Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia
Open Access
- 28 August 2012
- Vol. 119 (1), 115-125
- https://doi.org/10.1002/cncr.27650
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up DataJournal of Clinical Oncology, 2010
- Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemiaBlood, 2010
- Treatment of elderly adults with acute promyelocytic leukemia: put the pedal to metal.Leukemia & Lymphoma, 2009
- Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicityBlood, 2006
- Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapyAnnals Of Oncology, 2005
- All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemiaBlood, 2004
- Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experienceLeukemia, 2004
- Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocolsLeukemia, 2003
- A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic LeukemiaBlood, 1999
- Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid: Result of the Randomized MRC TrialBlood, 1999